Founded in 2020, Signet Therapeutics is developing targeted small molecule cancer drugs using novel disease models. Dr. Haisheng Zhang, CEO of Signet Therapeutics, and his core team members originate from Dana-Farber Cancer Institute, Harvard Medical School. The company says that traditional in vitro studies use cell lines that cannot accurately model patient’s drug performance, often […]

View post to subscribe to site newsletter.

Quris is developing a fully automated, self-training AI platform designed to better predict clinical safety and efficacy for new drug candidates. The company is pioneering clinical trials on chips, which involves testing thousands of novel drug candidates on hundreds of stem-cells-derived “patients-on-a-chip”. Its fully automated, self-training AI platform is designed to accurately predict clinical safety […]

View post to subscribe to site newsletter.

Founded in 2020, Regain Therapeutics is pursuing a new treatment approach for Alzheimer’s disease which focuses on replenishing soluble amyloid-beta peptides in the brain rather than removing the corresponding accumulation of amyloid plaques. The company has been founded based on research discoveries and patent-pending technologies developed at Karolinska Institute in Sweden in collaboration with The […]

View post to subscribe to site newsletter.